<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04491929</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-111-20</org_study_id>
    <nct_id>NCT04491929</nct_id>
  </id_info>
  <brief_title>Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases</brief_title>
  <acronym>SIRT</acronym>
  <official_title>Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases - SIRT - A Translational Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational, feasibility study investigating biological aspects in patients with liver&#xD;
      metastasis from colorectal cancer undergoing treatment with SIRT, by translational analysis&#xD;
      of biological samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators seek to investigate biological aspects in patients with&#xD;
      colorectal cancer liver metastasis undergoing treatment with Selective Internal Radiation&#xD;
      Therapy, by translational analysis of biological samples.&#xD;
&#xD;
      SIRT will be conducted as per standard procedure at Aarhus University Hospital. Translational&#xD;
      blood samples will be drawn pre-treatment and during follow up.&#xD;
&#xD;
      The total cell free DNA level will be quantified in all samples. The samples will be analysed&#xD;
      for tumour specific mutations such as the KRAS, BRAF and NRAS oncogenes.&#xD;
&#xD;
      The investigators expect to include up to 30 patients.&#xD;
&#xD;
      This is a purely observational translational study. Results will be analysed in relation to&#xD;
      outcome data.&#xD;
&#xD;
      The study is conducted in collaboration with:&#xD;
&#xD;
      Department of Gastroenterology and Hepatology, Aarhus University Hospital Department of&#xD;
      Radiology, Aarhus University Hospital Department of Nuclear Medicine, Aarhus University&#xD;
      Hospital&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2028</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility and translational analysis</measure>
    <time_frame>When 5 patients are included, the blood samples will be analysed for explorative analysis (expected after the first year). In all we expect to include 30 patients if positive results.</time_frame>
    <description>Investigating potential prognostic and predictive markers for efficacy by molecular characteristics and mutational analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>6 months</time_frame>
    <description>According to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Liver Metastasis Colon Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of patients with metastatic colorectal cancer with&#xD;
        chemorefractory liver dominant disease. Patients are found not eligible for surgical&#xD;
        resection, RFA or SBRT by a multidisciplinary tumour board (MDT), and considered candidates&#xD;
        for SIRT treatment in order to obtain disease control or resectability.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of metastatic colorectal adenocarcinoma with liver dominant disease&#xD;
&#xD;
          -  Diagnosis of liver metastasis may be made by histo- or cyto-pathology, or by clinical&#xD;
             and imaging criteria.&#xD;
&#xD;
          -  The Liver metastasis are not eligible for resection, RFA or SBRT&#xD;
&#xD;
          -  All patients must be off all chemotherapeutic regimens for 14 days prior to SIRT&#xD;
             treatment&#xD;
&#xD;
          -  All patients must be off vascular endothelial growth factor inhibitors for 6 weeks&#xD;
             prior to SIRT treatment&#xD;
&#xD;
          -  Progressive disease, severe intolerance during or following all standard lines of&#xD;
             chemo-therapy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Able to understand written information&#xD;
&#xD;
          -  Consent to samples for translational research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pretherapeutic work-up procedure with Tc-99m macroaggregated albumin (MAA)&#xD;
             scintigraphy showing extrahepatic foci in GI-tract&#xD;
&#xD;
          -  Evidence of any detectable Tc-99m macroaggregated albumin deposition in the stomach or&#xD;
             duodenum, after application of established angiographic techniques to stop such&#xD;
             deposition&#xD;
&#xD;
          -  Previous radiation therapy to the lungs and/or to the upper abdomen overlapping with&#xD;
             dose to the liver at interventionist´s decision&#xD;
&#xD;
          -  Lung shunt greater than 20% or &gt; 30 Gray radiation absorbed dose to the lungs, at&#xD;
             estimated by Tc-99m-MAA&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Symptomatic lung disease precluding SIRT at interventionist´s decision&#xD;
&#xD;
          -  Active uncontrolled infection&#xD;
&#xD;
          -  Any pre-treatment laboratory findings within 30 days of treatment demonstrating:&#xD;
             alanine aminotransferase level greater than 5 times upper normal limit and/or serum&#xD;
             bilirubin greater than 2 mg/dl (&gt;34 umol/l)&#xD;
&#xD;
          -  Current or previously evidence of ascites on CT-scan or physical examination&#xD;
&#xD;
          -  Tumour volume greater than 50% of liver volume&#xD;
&#xD;
          -  Conditions precluding translational samples&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louise B Callesen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Experimental Clinical Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Louise B Callesen, MD</last_name>
    <phone>+4578462535</phone>
    <email>louicall@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Oncology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <state>Danmark</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise B Callesen, MD</last_name>
      <phone>30482884</phone>
      <email>louicall@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Louise Bach Callesen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Liver metastasis Colon Cancer</keyword>
  <keyword>Circulating Tumour DNA</keyword>
  <keyword>Selective Internal Radiation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

